Pyxis Oncology Stock Slides -71% With A 6-Day Losing Spree
Pyxis Oncology (PYXS) stock hit day 6 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -71% return. The company has lost about $195 Mil in value over the last 6 days, with its current market capitalization at about $79 Mil. The stock remains 18.3% below its value at the end of 2024. This compares with year-to-date returns of 16.2% for the S&P 500.
Pyxis Oncology’s shares plunged following preliminary Phase 1 data for MICVO. While efficacy showed a 46% ORR (monotherapy) and 71% (combination), the market reacted negatively to a 28% treatment discontinuation rate due to adverse events, overshadowing promising responses and an extended cash runway.
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.For quick background, PYXS offers development of immune-oncology therapies, including a siglec-15 targeting antibody for treating thyroid cancer, head and neck squamous cell carcinoma, NSCLC, and other solid tumors.
Comparing PYXS Stock Returns With The S&P 500
- How To Earn 8.2% Yield While Waiting to Buy WYNN 30% Cheaper
- What Could Light a Fire Under Costco Wholesale Stock
- The Hidden Dangers Facing Amazon.com Stock
- Cash Rich, Low Price – Ardent Health Stock to Break Out?
- Momentum Meets Value: Centrus Energy Stock Could Be A Good Buy
- High Margins, 34% Discount: Buy Visa Stock Now
The following table summarizes the return for PYXS stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | PYXS | S&P 500 |
|---|---|---|
| 1D | -26.3% | 0.9% |
| 6D (Current Streak) | -71.1% | -1.0% |
| 1M (21D) | -72.1% | 2.9% |
| 3M (63D) | -41.2% | 2.1% |
| YTD 2025 | -18.3% | 16.2% |
| 2024 | -13.3% | 23.3% |
| 2023 | 34.3% | 24.2% |
| 2022 | -87.8% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 45 S&P constituents with 3 days or more of consecutive gains and 30 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 34 | 7 |
| 4D | 7 | 16 |
| 5D | 2 | 2 |
| 6D | 0 | 5 |
| 7D or more | 2 | 0 |
| Total >=3 D | 45 | 30 |
Key Financials for Pyxis Oncology (PYXS)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $16.1 Mil |
| Operating Income | $-82.2 Mil | $-68.5 Mil |
| Net Income | $-73.8 Mil | $-77.3 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $2.8 Mil | $0 |
| Operating Income | $-19.8 Mil | $-23.5 Mil |
| Net Income | $-18.4 Mil | $-22.0 Mil |
The losing streak PYXS stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.